Syntara stock (April 2026) | Growth, Valuation & Analysis

Syntara

ASX:SNT

$ 0,03

$0,00 (0,00%)

0,03 $

$0,00 (0,00%)

End-of-day quote: 04/10/2026

Syntara Stock Value

The current analyst rating for Syntara is Buy.

Buy

Syntara Company Info

EPS Growth 5Y

19,73%

Market Cap

$0,06 B

Long-Term Debt

$0,01 B

Quarterly earnings

N/A

Dividend

$0,00

Dividend Yield

0,00%

Founded

1998

Industry

Information Technology

Country

Australia

Website

Syntara

ISIN Number

AU0000312480

Website

http://syntaratx.com.au

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$0,13

333.33%

Last Update: 04/11/2026

Analysts: 2

Highest Price Target $0,19

Average Price Target $0,13

Lowest Price Target $0,06

In the last five quarters, Syntara’s Price Target has fallen from $0,32 to $0,20 - a -37,50% decrease. One analysts predict that Syntara’s share price will increase in the coming year, reaching $0,13. This would represent an increase of 333,33%.

Top growth stocks in the information technology sector (5Y.)

What does Syntara do?

Syntara Limited is a biotechnology company that specializes in the development of innovative therapies for chronic and serious human diseases. Business Segments The company operates through two primary segments, which are configured around its product development initiatives: Mannitol Respiratory Business This segment focuses on the clinical development, manufacture, and sale of two specific products-Bronchitol and Aridol. Bronchitol is used in the treatment of cystic fibrosis, while Aridol...

Syntara Limited is a biotechnology company that specializes in the development of innovative therapies for chronic and serious human diseases.

Business Segments

The company operates through two primary segments, which are configured around its product development initiatives:

Mannitol Respiratory Business

This segment focuses on the clinical development, manufacture, and sale of two specific products-Bronchitol and Aridol. Bronchitol is used in the treatment of cystic fibrosis, while Aridol is designed for bronchial challenge testing, a procedure widely used to diagnose asthma. This segment monitors the performance of these products collectively, assessing both market penetration and clinical efficacy in treating respiratory diseases. The sales of Bronchitol and Aridol are conducted on a global scale, allowing the company to serve a diverse range of markets and meet the needs of patients across various demographics. The company sustains its growth within this segment through ongoing investment in clinical trials, regulatory compliance, and robust marketing strategies.

New Drug Development

This segment encompasses the drug discovery and early-stage clinical development of the company's new drug candidates. The company employs advanced scientific research and innovative methodologies to develop new therapies. This segment plays a pivotal role in expanding the company's portfolio and future revenue streams, as it identifies potential drugs that can address unmet medical needs. Current projects may involve partnerships with other biotechnology firms or academic institutions, aimed at maximizing the clinical potential of new drug candidates. The company is focused on navigating the complexities of drug development, from preclinical research through to early-phase clinical trials, thereby ensuring rigorous scientific validation of its candidates before launch.

Business Strategy

The strategy of the company is directed towards enhancing its capabilities in innovation, product development, and market reach.

Products and Services

The company provides a range of products and services that primarily fall within the biotechnology sphere. The company's key offerings include:

Bronchitol

An inhalation powder used as a therapy for cystic fibrosis. It serves to help clear mucus from the lungs, thereby improving respiratory function in patients.

Aridol

A test for diagnosing asthma and other respiratory conditions. It allows clinicians to measure airway hyper-responsiveness in patients through bronchial challenge testing.

New Drug Candidates

The company is involved in the discovery and early-stage clinical development of new drugs targeting various chronic and serious diseases. These candidates have the potential to address significant unmet medical needs across different therapeutic areas.

In addition to its product offerings, the company also has capabilities in contract development through collaborative partnerships with other biotechnology firms. This aspect allows the company not only to expand its therapeutic portfolio but also to leverage its expertise in drug development to support third-party products.

Geographical Markets Served

The company operates in various geographical markets, including Australia and other international locations, to distribute its key products and services. The company continues to expand its global footprint by developing sales channels that effectively cater to the needs of healthcare providers and patients.

Customers

The company serves a variety of customers, primarily within the healthcare sector. The company caters to hospitals, clinics, health practitioners, and patients requiring innovative therapies for chronic diseases, especially those related to respiratory issues. The focus is on delivering effective treatments that can enhance quality of life and improve health outcomes.

Modes of Sales and Marketing

The company employs a multi-channel marketing strategy to facilitate the distribution of its products. The company utilizes direct sales teams and collaborates with third-party distributors and partners to ensure that its products reach healthcare professionals and patients efficiently. The marketing approach emphasizes awareness-building among healthcare practitioners and stakeholders, showcasing the characteristics and benefits of its product offerings.

Sales efforts are complemented by educational initiatives that aim to inform both practitioners and patients about the importance of proper treatment regimens, aiding the overall adoption of the company's therapies in clinical environments.

Government Regulations and Environmental Laws

The company operates under strict adherence to government regulations relevant to the biotechnology sector. Additionally, the environmental impact of its manufacturing processes is subject to rigorous oversight, adhering to laws such as the Clean Air Act and other environmental protection regulations.

History

The company was founded in 1998. It was incorporated in 1998. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in 2023.

New support ticket

Explore

Syntara Stock Value

Syntara Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the information technology sector (5Y.)

What does Syntara do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Syntara Stock Value

Syntara Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the information technology sector (5Y.)

What does Syntara do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.